Degradation of Bradykinin by Neutral Endopeptidase (EC 3.4.24.11) in Cultured Human Endothelial Cells by Graf, K. et al.
Graf el al.: Degradation of bradykinin by neutral endopeptidase 267
Eur. J. Clin. Chem. Clin. Biochem.
Vol. 31, 1993, pp. 267-272
© 1993 Walter de Gruyter & Co.
Berlin · New York
Degradation of Bradykinin by Neutral Endopeptidase (EC 3.4.24.11)
in Cultured Human Endothelial Cells
By K. Graf, M. Gräfe1, C. Bossaller1, J. Niehus2, K.-D. Schulz2, W. Auch-Schwelk1 and E. Fleck1
1 Department of Cardiology,. German Heart institute Berlin, Berlin, Germany
2 Department of Clinical Immunology and Asthma OPD, Free University Berlin, Berlin, Germany
(Received June 3/November 30, 1992)
Summary: The presence of neutral endopeptidase 24.11 was demonstrated in human umbilical vein endothelial
cells by immunostaining. Enzymatic activity of neutral endopeptidase was determined as 0.167 + 0.02 mU/mg
protein in the membrane fraction of human umbilical vein endothelial cells, using the fluorogenic peptide
substrate, dansyl-Z>-Ala-Gly-Phe(/?NO2)-Gly. No activity was found in the cytosolic fraction of endothelial
cells. The role of this peptidase in the degradation of the endogenous vasodilator bradykinin was investigated
by incubating human umbilical vein endothelial cell monolayers with bradykinin (10~8 mol/1). The inhibitor
of neutral endopeptidase, phosphoramidon (10""8 mol/1), decreased the degradation of bradykinin in the
supernatant of endothelial cells; the half-life of bradykinin was then increased from 29 + 1 to 46 ± 2 minutes.
The angiotensin-converting enzyme inhibitor, lisinopril (10~8 mol/1), increased the half-life of bradykinin to
244 + 20 minutes; the combination of both inhibitors increased the half-life of bradykinin to 381 ± 51
minutes. Inhibitors of aminopeptidase (amastatin) and carboxypeptidase (2-mercaptomethyl-3-guanidinoethyl-
thiopropionic acid) caused no significant effect. The effect of phosphoramidon was small in comparison with
that of lisinopril, but was pronounced in combination with lisinopril. Neutral endopeptidase activity is
localized in the membranes of human endothelial cells and seems to be involved in the degradation of
bradykinin by the vascular endothelium, particularly during angiotensin converting enzyme inhibition.
Introduction
prostacyclin from vascular endothelial cells (1). An-
The emerging importance of vasoactive peptides in giotensin converting enzyme1) accounts for the major
the regulation of vascular tone has directed interest part of kininase activity in human endothelial cells
to enzymes which could be involved in their local (2, 3). However, the role of other enzymes in the
generation and degradation. Bradykinin acts as a endothelial degradation of kinins is not precisely
potent vasodilator by inducing the rapid release of known. Other pathways of vasoactive peptide de-
endothelium-derived relaxing factor, nitric oxide, and gradation in the vascular endothelium may be of
particular interest when angiotensin converting en-
zyme is inhibited. A second kininase II1), which is
Enzymes identical to neutral endopeptidase1), has been de-
Neutral endopeptidase = Membrane metailo-endopeptidase, scribed in the brush border of the kidney (4) and
EC 3.4.24.11 appears to be involved in the renal degradation ofsissiiarijSiss"Kininase"=Dipeptidyl kinins ̂ -we theref°re ̂ ^^ ** p«*** °f
Aminopeptidase, EC 3.4.11.11 neutral endopeptidase and its role in the degradation
Carboxypeptidase = Serine carboxypeptidase, EC 3.4.16.1 of bradykinin in cultured human endothelial cells.
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Materials and Methods
Cell c u l t u r e
Human umbilical vein endothelial cells were prepared according
to the method of Jaffe (6) with minor modifications (7). Cells
of the second passage were used throughout ail experiments.
The purity and identity of the endothelial cell cultures was
verified by the presence of factor VIII related antigen (Dako,
Hamburg] Germany) and the uptake of fluorescence conju-
gated-low density lipoprolein (Paesel & Lorei, Frankfurt, Ger-
many).
Samples of 0.3 ml were taken at 15, 30 and 60 minutes, mixed
with 0.3 ml 0.2 mol/1 Tris + 0.01 mol/l EDTA buffer (pH 6.4),
frozen immediately in liquid nitrogen, and stored at — 70 °C
until further use. In experiments with lisinopril, the bradykinin
concentration was determined over an incubation period of 240
minutes. No bradykinin immunore btivity was detected in the
incubation medium, the cell supernatant and the stock solution
of the used peptidase inhibitors. No bradykinin degradation
was observed in the 4 hour incubation period in cell free
incubation medium at 37 °C.
Membrane prepara t ion of human umbil ical vein
e n d o t h e l i a l cells
Confluent monolayers were washed with ice-cold 50 mmol/1
Tris-HCl buffer, scraped off the dish with a rubber policeman
and centrifuged at 400 g for 4 minutes. The cell pellet was lysed
with ice-cold distilled water and centrifuged at 56 000 £ for 35
minutes. The 56000g membrane fraction and the supernatant
were aliquotted and frozen immediately. Protein concentration
was determined by the method of Lowry et al. (8).
Bradykinin radioimmunoassay
Immunoreactive kinins were measured by a radioimmunoassay
(RIA) as described previously (10, 11). The minimal amount
of bradykinin distinguishable from zero was 2 pg and thus the
detection limit of the RIA was 20 ng per litre of cell supernatant
medium. The inter- and intra-assay coefficients of variation
were 4% and 5%, respectively. The cross reactivity was less
than 1% to des-9arg-bradykinin. The peptidase inhibitors
added to the incubation medium did not interfere with the RIA
at the concentrations used in the experiments.
Immunos ta in ing
Cytocentrifuge preparations of human umbilical vein endothe-
lial cells were stained with an anti-human neutral endopeptidase
antibody ALB1 (Dianova, Hamburg, Germany), using the al-
kaline phosphatase anti-alkaline phosphatase method (9).
Flow cytometry
The endothelial cells were labelled with fluorescence-conjugated
ALB1 antibody. Cell counting and quantitation of fluorescence
activity of endothelial cells were performed with a flow cyto-
metry analyser (Becton-Dickinson, Heidelberg, Germany).
Calculations and statistics
Experiments were performed in triplicate. Results are shown as
means ± SEM (n = number of dishes or experiments). The
bradykinin half-life was calculated by linear regression analysis
in each experiment from the degradation of bradykinin during
the first 60 minutes. In experiments with lisinopril, the half-life
was calculated from the bradykinin degradation during the first
240 minutes. Statistical significance was analysed by the Mann-
Whitney-\J Test for unpaired samples. P values less than 0.05
were accepted as statistically significant.
Assay for neutral endopeptidase ac t iv i ty
in endothel ial cell f ract ions
The assay, which has been described in detail by Florentin &
Roques (10), employs dansyl-D-Ala-Gly-PheO?NO2)-Gly as the
substrate for neutral endopeptidase (Km = 45 μιηοΐ/ΐ, V = 0.65
μηιοΐ/πιίη). Measurements were performed with 50 μηηοΐ/ΐ dan-
syl-£-Ala-Gly-Phe(pNO2)-Gly in 50 mmol/1 Tris-HCl buffer in
the presence of phosphoramidon (10~s mol/1, Sigma, M nchen,
Germany) or diluent (for total activity) at a pH of 7.4 and
37 °C over a period of 24 hours. The increase of fluorogenic
activity was measured at 562 nm with a fluorescence spectro-
meter (Pharmacia, Freiburg, Germany). Enzymatic activity was
defined as the amount of substrate (dansyl-D-Ala-Gly-
Phe(/7NO2)-Gly) cleaved at 37 °C per minute (nmol/min · mg
protein = mU/mg protein) and was calculated from the max-
imal slope of the degradation curve. The activity inhibited by
phosphoramidon was assigned to neutral endopeptidase activ-
ity.
Degradation of b radykin in
The degradation of bradykinin was measured using intact en-
dothelial cell monolayers, seeded into 35 mm dishes (Falcon,
Heidelberg, Germany), and grown to confluency. Phosphor-
amidon (10~8 mol/1), lisinopril, (10~6, ICI, Plankstadt, Ger-
many) amastatin (10~5 mol/1, Sigma, M nchen, Germany) and
£>L-2-mercaptomethyl-3-guanidinoethyl-thiopropionic acid
(10~4 mol/1, Calbiochem, Frankfurt/Main, Germany) were
added to the incubation medium (RPMI, 10 g/1 bovine serum
albumin, 10 mmol/1 HEPES) 15 min before the addition of
bradykinin stock solution (Sigma, M nchen, Germany) in pep-
tide free medium to a final concentration of 10 μg/l bradykinin.
Results
Immunohistochemistry
Staining with the anti-human neutral endopeptidase
antibody demonstrated the presence of neutral en-
dopeptidase antigen (fig. 1). Control staining without
the anti-neutral endopeptidase antibody resulted in
low unspecific binding of the alkaline-phosphatase
complex. Flow cytometry analysis showed that
67 + 6% (n = 4) of endothelial cells express neutral
endopeptidase antigen on their cell membrane.
Neutral endopeptidase activity
The activity of endothelial neutral endopeptidase was
measured in the 56 000 g crude membrane preparation
of human umbilical vein endothelial cells. In the mem-
brane preparation, a neutral endopeptidase activity
of 167 + 1.7 μΐΐ/mg protein (mean values ± SEM;
ή = 6) was measured. No neutral endopeptidase ac-
tivity was detected in the supernatant of the 56 000 g
fraction, which mainly consists of cytosolic particles
(fig. 2).
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Fig. 1. Light micrograph of human umbilical vein endothelial cells stained with an antibody directed against neutral endopeptidase























Fig. 2. Time course of dansyUJD.Ala-Gly-PheO?NO2)-Gly (50
μηιο1/1) degradation by crude membrane preparation of
human umbilical vein endothelial cells (56 000 £ frac-
tion) (o) and the cytosol fraction (·) (n = 6 each) in
50 mmol/1 Tris-HCl buffer, pH 7.4, at 37 °C. Data
represent the specific neutral endopeptidase activity,
which was inhibited by phosphoramidon (10~8 mol/1).
Endothelial degradation of bradykin in
In the supernatant of confluent endothelial monolay-
ers, the decrease of 10~8 mol/1 exogeneous bradykinin
shows a time dependent kinetic (fig. 3) in the absence
of inhibitors. The rapid degradation during the first
15 minutes is followed by a slow degradation during
the following time period. In the presence of phos-
phoramidon (10~8 mol/1) significantly higher brady-
kinin concentrations were measured in the superna:
tant of human umbilical vein endothelial cells com-
pared with the control (p < 0.05, η = 9). The angio-
tensin converting enzyme inhibitor, lisinopril, inhib-
ited most of the bradykinin degradation by intact
endothelial monolayers. After 240 min incubation
with phosphoramidon in the presence of lisinopril,
the bradykinin concentration was significantly higher
than after incubation with lisinopril alone (lisinopril:
3680 ± 458 ng/1, n = 12); lisinopril + phosphor-
amidon: 5060 ± 568 ng/1, n = 9; p < 0.03 vs. lisi-
nopril).
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Fig. 3. Time course of degradation of exogeneous bradykinin
in the absence (control, circle) and presence of lisinopril
(10~6 mol/1, filled triangle), phosphoraraidon (10~8
raol/1, open triangle) and the combination of phos-
phoramidon and lisinopril in the supernatant of a con-
fluent monolayer of endothelial cells (human umbilical
vein endothelial cells; n = 9-16, * = P< 0.05 vs. con-
trol, ** = P < 0.01 vs. control).
500 r
Fig. 4. Half-lives of bradykinin in the presence or absence of
various peptidase inhibitors phosphoramidon, 10~8
mol/1; lisinoprii, 10~6 mol/1; amastatin, 10~6 mol/1; DL-
mercaptomethyl-guanidinoethyl-thiopropionic acid,
10~4 mol/1; mean ± SEM minutes; * = P < 0.05 vs.
control, ** = P < 0.01 vs. control.
The half-life of bradykinin in the absence of inhibitors
was 29 ±1 minutes (n = 18) and it was prolongated
up to 244 + 20 minutes (n = 15, p < 0.005) in the
presence of the angiotensin converting enzyme inhib-
itor, lisinopril. Phosphoramidon alone significantly
prolonged the half-life of bradykinin up to 46 ± 2
minutes (n = 15, p < 0.01; fig.4). The addition of
phosphoramidon to lisinopril resulted in a significant
prolongation of the half-life up to 381 ± 51 minutes
(n = 12, L vs. L + P p < 0.03). The half-life of bra-
dykinin in the presence of all inhibitors (lisinopril,
amastatin, phosphoramidon, /)L-2-mercaptomethyl-
3-guanidinoethyl-thiopropionic acid) did not exceed
the half-life of bradykinin in the presence of the com-
bination of lisinopril and phosphoramidon
(L + P + A: 386 ± 52 minutes, n = 12;
L + p + A + M: 275 ±22 minutes, n = 9). The
combination of both inhibitors with amastatin and
Z)L-2-mercaptomethyl-3-guanidinoethyl-thiopro-
pionic acid affected the half-life of bradykinin.
It is estimated that the degradation of bradykinin by
neutral endopeptidase, as judged from the prolonga-
tion of the bradykinin half-life, is equivalent to about
9% of the degradation due to angiotensin converting
enzyme activity.
Discussion
Our study shows that two kininases are largely re-
sponsible for the degradation of the vasoactive pep-
tide, bradykinin, by intact endothelial cells in culture,
i.e. angiotensin converting enzyme and neutral en-
dopeptidase. The decay of the bradykinin concentra-
tion indicated that about 90% of bradykinin is de-
graded by angiotensin converting enzyme, whereas
the minor part is cleaved by neutral endopeptidase.
Aminopeptidase1) or carboxypeptidase1) activity
seems not to play a role in bradykinin degradation
by intact endothelial cells.
In order to verify the presence of neutral endopepti-
dase we performed alkaline phosphatase staining of
human endothelial cells with a monoclonal mouse
antibody. Quantification by flow cytometry analysis
performed with the same antibody detected 67% an-
tigen-positive cells. Since the antibody was incubated
with intact living cells and could not penetrate the
cellular membrane this result indicates the presence
of neutral endopeptidase on the surface of endothelial
cells.
This corresponds to the results of the functional assay
with the artificial substrate, dansyl-Z>-Ala-Gly-
Phe(pNO2)-Gly, which show considerable neutral en-
dopeptidase-activity in the membrane preparations of
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human endothelial cells. Neutral endopeptidase activ-
ity was not, however, detected in the cytosolic frac-
tion. The lack of detectable neutral endopeptidase
activity in the soluble fraction indicates that this pep-
tidase is mainly located in the cellular membranes of
the endothelial cell, where it is in close contact with
circulating peptides. The enzymatic activity measured
in the membrane preparation corresponds to previ-
ously published data of Florentin and coworkers for
various rat tissues (10).
The vascular endothelium plays an important role in
the regulation of the vascular tone. We used the con-
fluent living endothelial monolayer to study the de-
gradation of physiologically effective concentrations
of bradykinin, a potent vasodilator. Our data show
that living endothelium degrades bradykinin by en-
zymatic cleavage, and that this was prevented by two
specific inhibitors. The neutral endopeptidase inhibi-
tor, phosphoramidon, significantly diminished the
bradykinin degradation after 30 and 60 minutes, al-
though angiotensin converting enzyme activity was
not blocked. The time curve of bradykinin degrada-
tion indicates that the major decrease during the first
30 minutes is not observed in the presence of the
angiotensin converting enzyme inhibitor, lisinopril.
We therefore attributed this fall of bradykinin con-
centration to the dominant role of angiotensin con-
verting enzyme in the endothelial bradykinin degra-
dation.
By calculating the half-life of bradykinin in presence
of intact endothelium, we detected a significant effect
of phosphoramidon. This effect was pronounced
when the angiotensin converting enzyme inhibitor,
lisinopril, was present, indicating a physiological role
of neutral endopeptidase in the degradation of bra-
dykinin during angiotensin converting enzyme inhi-
bition. The combination of lisinopril and phosphor-
amidon almost prevented the bradykinin degradation,
indicating the presence of a low undefined additional
kininase activity on intact endothelial cells. These
activities cannot be attributed to aminopeptidase or
carboxypeptidase, since their inhibitors, amastastin
and/)L-2-mercaptomethyl-3-guanidinoethyl-thiopro-
pionic acid, are without effect. The present data are
consistent with the hypothesis of an additional role
of endothelial neutral endopeptidase in the local de-
gradation of bradykinin, besides angiotensin convert-
ing enzyme, in intact endothelium.
In a recently published study (13), which investigated
bradykinin-induced vascular permeability in the ham-
ster cheek pouch, phosphoramidon, as well as the
angiotensin converting enzyme inhibitor, captopril,
significantly augmented the effect of bradykinin on
vascular leakage. Furthermore, neutral endopeptidase
located in the vascular endothelium is involved in the
cleavage of several other vasoactive peptides including
substance P, chemotactic peptide (N-Formyl-Met-
Leu-Phe), endothelin and angiotensin I (1, 14—18).
Recently, Solheilac and coworkers identified neutral
endopeptidase as a Mr 94000 membrane protein in
vascular membranes from rat and rabbit aorta. In
addition, they demonstrated the degradation of atrial
natriuretic peptide by neutral endopeptidase (19).
Thus, the neutral endopeptidase, which is present in
membranes of human endothelial cells, may contrib-
ute to the local degradation of bradykinin and other
vasoactive peptides by the vascular endothelium, par-
ticularly when angiotensin converting enzyme inhib-
itors are present.
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